This is a phase 3 trial enrolling subjects with newly diagnosed Corona virus disease 2019 ( COVID-19) infection who are classified as moderate cases and require hospitalization. Patients meeting eligibility criteria will be randomized either to receive oral N-acetylcysteine or not along with the institution treatment protocol . Treatment efficacy will be assessed using certain endpoints as follows:~Markers of inflammation and oxidative stress~Length of hospital stay~Need for ventilation~Mortality rate
The purpose of the study is to assess the potential therapeutic effect of N-acetylcysteine NAC in COVID 19 patients.